Stock Track | Tarsus Pharmaceuticals (TARS) Stock Surges 5.4% in Pre-Market on Strong XDEMVY Launch

Stock Track

Feb 25, 2025

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) soared 5.4% in pre-market trading on Tuesday, following the company's impressive fourth quarter and full-year 2024 financial results driven by the strong launch of its new eye drop XDEMVY for the treatment of Demodex blepharitis.

XDEMVY, the first FDA-approved pharmacologic treatment for Demodex blepharitis, generated net product sales of $66.4 million in Q4 2024 and $180.1 million for the full year. The product has seen broad adoption by eye care professionals across over 15,000 targets, and secured reimbursement covering more than 90% of insured lives.

While Tarsus reported a Q4 net loss of $23.1 million due to heavy investments in XDEMVY's commercial launch, management remained optimistic about the product's long-term prospects. The company is also advancing a promising pipeline, including a potential treatment for Ocular Rosacea that could drive future growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1164541968"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164541968\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164541968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164541968","market":"us","top_or_hot":-1,"title":"Stock Track | Tarsus Pharmaceuticals (TARS) Stock Surges 5.4% in Pre-Market on Strong XDEMVY Launch","media":"Stock Track","content":"<p>Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) soared 5.4% in pre-market trading on Tuesday, following the company's impressive fourth quarter and full-year 2024 financial results driven by the strong launch of its new eye drop XDEMVY for the treatment of Demodex blepharitis.</p>\n\n<p>XDEMVY, the first FDA-approved pharmacologic treatment for Demodex blepharitis, generated net product sales of $66.4 million in Q4 2024 and $180.1 million for the full year. The product has seen broad adoption by eye care professionals across over 15,000 targets, and secured reimbursement covering more than 90% of insured lives.</p>\n\n<p>While Tarsus reported a Q4 net loss of $23.1 million due to heavy investments in XDEMVY's commercial launch, management remained optimistic about the product's long-term prospects. The company is also advancing a promising pipeline, including a potential treatment for Ocular Rosacea that could drive future growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tarsus Pharmaceuticals (TARS) Stock Surges 5.4% in Pre-Market on Strong XDEMVY Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tarsus Pharmaceuticals (TARS) Stock Surges 5.4% in Pre-Market on Strong XDEMVY Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) soared 5.4% in pre-market trading on Tuesday, following the company's impressive fourth quarter and full-year 2024 financial results driven by the strong launch of its new eye drop XDEMVY for the treatment of Demodex blepharitis.</p>\n\n<p>XDEMVY, the first FDA-approved pharmacologic treatment for Demodex blepharitis, generated net product sales of $66.4 million in Q4 2024 and $180.1 million for the full year. The product has seen broad adoption by eye care professionals across over 15,000 targets, and secured reimbursement covering more than 90% of insured lives.</p>\n\n<p>While Tarsus reported a Q4 net loss of $23.1 million due to heavy investments in XDEMVY's commercial launch, management remained optimistic about the product's long-term prospects. The company is also advancing a promising pipeline, including a potential treatment for Ocular Rosacea that could drive future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TARS","symbol_name":"Tarsus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1164541968","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164541968","pubTimestamp":1740485911,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Tarsus Pharmaceuticals, Inc.  soared 5.4% in pre-market trading on Tuesday, following the company's impressive fourth quarter and full-year 2024 financial results driven by the strong launch of its new eye drop XDEMVY for the treatment of Demodex blepharitis.XDEMVY, the first FDA-approved pharmacologic treatment for Demodex blepharitis, generated net product sales of $66.4 million in Q4 2024 and $180.1 million for the full year. The product has seen broad adoption by eye care professio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"由于XDEMVY的强劲推出，Tarsus Pharmaceuticals(TARS)股价在盘前飙升5.4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) soared 5.4% in pre-market trading on Tuesday, following the company's impressive fourth quarter and full-year 2024 financial results driven by the strong launch of its new eye drop XDEMVY for the treatment of Demodex blepharitis.\nXDEMVY, the first FDA-approved pharmacologic treatment for Demodex blepharitis, generated net product sales of $66.4 million in Q4 2024 and $180.1 million for the full year. The product has seen broad adoption by eye care professionals across over 15,000 targets, and secured reimbursement covering more than 90% of insured lives.\nWhile Tarsus reported a Q4 net loss of $23.1 million due to heavy investments in XDEMVY's commercial launch, management remained optimistic about the product's long-term prospects. The company is also advancing a promising pipeline, including a potential treatment for Ocular Rosacea that could drive future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}